Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells
Cooperation between endothelial cells and bone in bone remodelling is well established. In contrast, bone microvasculature supporting the growth of primary tumors and metastasis is poorly understood. Several antiangiogenic agents have recently been undergoing trials, although an extensive body of cl...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/5/2/404 |
id |
doaj-e1e2138984094a2880f1ae32309354ea |
---|---|
record_format |
Article |
spelling |
doaj-e1e2138984094a2880f1ae32309354ea2020-11-24T23:54:07ZengMDPI AGCancers2072-66942013-04-015240441710.3390/cancers5020404Ex Vivo Behaviour of Human Bone Tumor Endothelial CellsGaetano ApiceCristina TutucciAnnarosaria De ChiaraFlavio FazioliMichele GalloElena CesarioTeresa InfanteFilomena de NigrisCooperation between endothelial cells and bone in bone remodelling is well established. In contrast, bone microvasculature supporting the growth of primary tumors and metastasis is poorly understood. Several antiangiogenic agents have recently been undergoing trials, although an extensive body of clinical data and experimental research have proved that angiogenic pathways differ in each tumor type and stage. Here, for the first time, we characterize at the molecular and functional level tumor endothelial cells from human bone sarcomas at different stages of disease and with different histotypes. We selected a CD31+ subpopulation from biopsies that displayed the capability to grow as adherent cell lines without vascular endothelial growth factor (VEGF). Our findings show the existence in human primary bone sarcomas of highly proliferative endothelial cells expressing CD31, CD44, CD105, CD146 and CD90 markers. These cells are committed to develop capillary-like structures and colony formation units, and to produce nitric oxide. We believe that a better understanding of tumor vasculature could be a valid tool for the design of an efficacious antiangiogenic therapy as adjuvant treatment of sarcomas.http://www.mdpi.com/2072-6694/5/2/404sarcomasangiogenesisendothelial cellstumor microenvironment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gaetano Apice Cristina Tutucci Annarosaria De Chiara Flavio Fazioli Michele Gallo Elena Cesario Teresa Infante Filomena de Nigris |
spellingShingle |
Gaetano Apice Cristina Tutucci Annarosaria De Chiara Flavio Fazioli Michele Gallo Elena Cesario Teresa Infante Filomena de Nigris Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells Cancers sarcomas angiogenesis endothelial cells tumor microenvironment |
author_facet |
Gaetano Apice Cristina Tutucci Annarosaria De Chiara Flavio Fazioli Michele Gallo Elena Cesario Teresa Infante Filomena de Nigris |
author_sort |
Gaetano Apice |
title |
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells |
title_short |
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells |
title_full |
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells |
title_fullStr |
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells |
title_full_unstemmed |
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells |
title_sort |
ex vivo behaviour of human bone tumor endothelial cells |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2013-04-01 |
description |
Cooperation between endothelial cells and bone in bone remodelling is well established. In contrast, bone microvasculature supporting the growth of primary tumors and metastasis is poorly understood. Several antiangiogenic agents have recently been undergoing trials, although an extensive body of clinical data and experimental research have proved that angiogenic pathways differ in each tumor type and stage. Here, for the first time, we characterize at the molecular and functional level tumor endothelial cells from human bone sarcomas at different stages of disease and with different histotypes. We selected a CD31+ subpopulation from biopsies that displayed the capability to grow as adherent cell lines without vascular endothelial growth factor (VEGF). Our findings show the existence in human primary bone sarcomas of highly proliferative endothelial cells expressing CD31, CD44, CD105, CD146 and CD90 markers. These cells are committed to develop capillary-like structures and colony formation units, and to produce nitric oxide. We believe that a better understanding of tumor vasculature could be a valid tool for the design of an efficacious antiangiogenic therapy as adjuvant treatment of sarcomas. |
topic |
sarcomas angiogenesis endothelial cells tumor microenvironment |
url |
http://www.mdpi.com/2072-6694/5/2/404 |
work_keys_str_mv |
AT gaetanoapice exvivobehaviourofhumanbonetumorendothelialcells AT cristinatutucci exvivobehaviourofhumanbonetumorendothelialcells AT annarosariadechiara exvivobehaviourofhumanbonetumorendothelialcells AT flaviofazioli exvivobehaviourofhumanbonetumorendothelialcells AT michelegallo exvivobehaviourofhumanbonetumorendothelialcells AT elenacesario exvivobehaviourofhumanbonetumorendothelialcells AT teresainfante exvivobehaviourofhumanbonetumorendothelialcells AT filomenadenigris exvivobehaviourofhumanbonetumorendothelialcells |
_version_ |
1725467206951632896 |